- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06609239
Dlouhodobé hodnocení bezpečnosti a účinnosti Lunsekimig (SAR443765) u dospělých účastníků se středně těžkým astmatem. (AIRPHRODITE)
Otevřená rozšířená studie k vyhodnocení dlouhodobé bezpečnosti a účinnosti subkutánního lunsekimigu u dospělých účastníků se středně těžkým astmatem, kteří se zúčastnili studie DRI16762
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.
The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.
Přehled studie
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina, 1121
- Investigational Site Number : 0320005
-
Buenos Aires, Argentina, 1414
- Investigational Site Number : 0320004
-
Buenos Aires, Argentina, 1425
- Investigational Site Number : 0320001
-
Buenos Aires, Argentina, 1122
- Investigational Site Number : 0320012
-
Buenos Aires, Argentina, 1425
- Investigational Site Number : 0320011
-
La Plata, Buenos Aires, Argentina, B1904CUL
- Investigational Site Number : 0320003
-
Mendoza, Argentina, 5500
- Investigational Site Number : 0320009
-
Mendoza, Argentina, 5500
- Investigational Site Number : 0320015
-
Santa Fe, Argentina, 3000
- Investigational Site Number : 0320010
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentina, 1886
- Investigational Site Number : 0320007
-
Lobos, Buenos Aires, Argentina, 7240
- Investigational Site Number : 0320013
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Investigational Site Number : 0320002
-
Rosario, Santa Fe Province, Argentina, 2000
- Investigational Site Number : 0320006
-
Rosario, Santa Fe Province, Argentina, 2000
- Investigational Site Number : 0320020
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Investigational Site Number : 0320008
-
-
-
-
-
Rio de Janeiro, Brazílie, 22241-180
- CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
-
São Paulo, Brazílie, 05403-000
- Incor - Instituto do Coracao- Site Number : 0760011
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazílie, 40060-330
- Associacao Proar- Site Number : 0760003
-
-
Goiás
-
Goiânia, Goiás, Brazílie, 74605-020
- Universidade Federal de Goias- Site Number : 0760007
-
-
Paraná
-
Curitiba, Paraná, Brazílie, 80030-110
- CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
-
-
Pernambuco
-
Recife, Pernambuco, Brazílie, 50070-550
- Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
-
-
Santa Catarina
-
Blumenau, Santa Catarina, Brazílie, 89030-101
- Hospital Dia do Pulmão- Site Number : 0760005
-
-
-
-
Biobio
-
Concepción, Biobio, Chile, 4070094
- Investigational Site Number : 1520013
-
-
Maule Region
-
Talca, Maule Region, Chile, 3465584
- Investigational Site Number : 1520001
-
-
Reg Metropolitana de Santiago
-
Recoleta, Reg Metropolitana de Santiago, Chile, 8420000
- Investigational Site Number : 1520015
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500587
- Investigational Site Number : 1520006
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500692
- Investigational Site Number : 1520005
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500698
- Investigational Site Number : 1520004
-
Santiago, Reg Metropolitana de Santiago, Chile, 7750495
- Investigational Site Number : 1520002
-
-
Valparaiso
-
Quillota, Valparaiso, Chile, 2260877
- Investigational Site Number : 1520008
-
Viña del Mar, Valparaiso, Chile, 2531172
- Investigational Site Number : 1520011
-
Viña del Mar, Valparaiso, Chile, 2540364
- Investigational Site Number : 1520012
-
-
-
-
-
Calicut, Indie, 673008
- Investigational Site Number : 3560007
-
Hyderabad, Indie, 500084
- Investigational Site Number : 3560009
-
Kanpur, Indie, 208001
- Investigational Site Number : 3560008
-
Nagpur, Indie, 441203
- Investigational Site Number : 3560001
-
Pune, Indie, 411057
- Investigational Site Number : 3560004
-
-
-
-
Roma
-
Rome, Roma, Itálie, 00168
- Investigational Site Number : 3800010
-
-
-
-
-
Ashkelon, Izrael, 7830604
- Investigational Site Number : 3760006
-
Haifa, Izrael, 3104802
- Investigational Site Number : 3760001
-
Haifa, Izrael, 3436212
- Investigational Site Number : 3760008
-
Jerusalem, Izrael, 9103102
- Investigational Site Number : 3760003
-
Jerusalem, Izrael, 9112001
- Investigational Site Number : 3760002
-
Petah Tikva, Izrael, 4941492
- Investigational Site Number : 3760010
-
Rehovot, Izrael, 7610001
- Investigational Site Number : 3760004
-
Tel Aviv, Izrael, 6423906
- Investigational Site Number : 3760007
-
-
-
-
-
Fukushima, Japonsko, 960-1295
- Investigational Site Number : 3920008
-
Kyoto, Japonsko, 610-0113
- Investigational Site Number : 3920006
-
Kyoto, Japonsko, 612-8555
- Investigational Site Number : 3920009
-
Miyazaki, Japonsko, 889-1692
- Investigational Site Number : 3920012
-
-
Kagawa-ken
-
Sakaidechō, Kagawa-ken, Japonsko, 762-8550
- Investigational Site Number : 3920002
-
-
Tokyo
-
Chūō, Tokyo, Japonsko, 104-0031
- Investigational Site Number : 3920011
-
-
Yamaguchi
-
Ube, Yamaguchi, Japonsko, 755-8505
- Investigational Site Number : 3920005
-
-
-
-
-
Benoni, Jižní Afrika, 1500
- Investigational Site Number : 7100004
-
Benoni, Jižní Afrika, 1500
- Investigational Site Number : 7100005
-
Cape Town, Jižní Afrika, 7530
- Investigational Site Number : 7100003
-
Cape Town, Jižní Afrika, 7700
- Investigational Site Number : 7100002
-
Durban, Jižní Afrika, 4001
- Investigational Site Number : 7100001
-
Pretoria, Jižní Afrika, 0157
- Investigational Site Number : 7100006
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Jižní Korea, 03722
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Jižní Korea, 03080
- Investigational Site Number : 4100002
-
Seoul, Seoul-teukbyeolsi, Jižní Korea, 05030
- Investigational Site Number : 4100004
-
Seoul, Seoul-teukbyeolsi, Jižní Korea, 05505
- Investigational Site Number : 4100006
-
Seoul, Seoul-teukbyeolsi, Jižní Korea, 06351
- Investigational Site Number : 4100005
-
-
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S 2J5
- Investigational Site Number : 1240013
-
Hamilton, Ontario, Kanada, L8N 4A6
- Investigational Site Number : 1240003
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Investigational Site Number : 1240004
-
Trois-Rivières, Quebec, Kanada, G8T 7A1
- Investigational Site Number : 1240001
-
-
-
-
-
Mosonmagyaróvár, Maďarsko, 9200
- Investigational Site Number : 3480004
-
-
-
-
-
Chihuahua City, Mexiko, 31000
- Investigational Site Number : 4840002
-
Durango, Mexiko, 34000
- Investigational Site Number : 4840003
-
Veracruz, Mexiko, 91900
- Investigational Site Number : 4840008
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexiko, 66465
- Investigational Site Number : 4840004
-
-
Querétaro
-
San Juan del Río, Querétaro, Mexiko, 76800
- Investigational Site Number : 4840005
-
-
Yucatán
-
Mérida, Yucatán, Mexiko, 97070
- Investigational Site Number : 4840007
-
-
-
-
-
Leipzig, Německo, 04347
- Investigational Site Number : 2760001
-
Mainz, Německo, 55128
- Investigational Site Number : 2760005
-
-
-
-
-
Chęciny, Polsko, 26-060
- Investigational Site Number : 6160004
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polsko, 60-693
- Investigational Site Number : 6160001
-
-
-
-
-
Bradford, Spojené království, BD9 6DA
- Investigational Site Number : 8260008
-
Chertsey, Spojené království
- Investigational Site Number : 8260005
-
London, Spojené království, W1G 8HU
- Investigational Site Number : 8260011
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Spojené království, CB2 2QQ
- Investigational Site Number : 8260001
-
-
Glasgow City
-
Glasgow, Glasgow City, Spojené království, G12 0YN
- Investigational Site Number : 8260004
-
-
-
-
Arizona
-
Chandler, Arizona, Spojené státy, 85224
- Chandler Clinical Research Trials- Site Number : 8400075
-
Tucson, Arizona, Spojené státy, 85712
- Tucson Clinical Research Institute- Site Number : 8400085
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80014
- Allianz Research Institute - Aurora- Site Number : 8400026
-
Wheat Ridge, Colorado, Spojené státy, 80033
- Western States Clinical Research- Site Number : 8400014
-
-
Florida
-
Boynton Beach, Florida, Spojené státy, 33435
- Helix Biomedics- Site Number : 8400114
-
Cutler Bay, Florida, Spojené státy, 33157
- Beautiful Minds Clinical Research Center- Site Number : 8400049
-
Hialeah, Florida, Spojené státy, 33010
- Qway Research - Hialeah- Site Number : 8400015
-
Miami, Florida, Spojené státy, 33184
- High Quality Research- Site Number : 8400039
-
Miami, Florida, Spojené státy, 33186
- Innovations Biotech- Site Number : 8400040
-
Miami, Florida, Spojené státy, 33186
- New Access Medical Center- Site Number : 8400043
-
Miami, Florida, Spojené státy, 33135
- Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
-
Miami Lakes, Florida, Spojené státy, 33014
- Deluxe Health Center- Site Number : 8400045
-
Pembroke Pines, Florida, Spojené státy, 33025
- Tellabio International Research Services- Site Number : 8400083
-
Pembroke Pines, Florida, Spojené státy, 33029
- Alfa Medical Research LLC- Site Number : 8400146
-
Pensacola, Florida, Spojené státy, 32503
- Avanza Medical Research Center- Site Number : 8400135
-
Saint Cloud, Florida, Spojené státy, 34769
- Ilumina Medical Research- Site Number : 8400095
-
Sarasota, Florida, Spojené státy, 34239
- Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
-
-
Georgia
-
Cordele, Georgia, Spojené státy, 31015
- Private Practice - Dr. David Kavtaradze- Site Number : 8400081
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Brigham & Women's Hospital- Site Number : 8400034
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63141
- Midwest Clinical Research Center - St. Louis- Site Number : 8400006
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28287
- Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
-
-
Ohio
-
Toledo, Ohio, Spojené státy, 43617
- Asthma & Allergy Center - Toledo- Site Number : 8400017
-
-
Oklahoma
-
Edmond, Oklahoma, Spojené státy, 73034
- OK Clinical Research- Site Number : 8400021
-
-
Pennsylvania
-
DuBois, Pennsylvania, Spojené státy, 15801
- Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
-
Pittsburgh, Pennsylvania, Spojené státy, 15241
- Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
-
-
Texas
-
Austin, Texas, Spojené státy, 78759
- Orion Clinical Research- Site Number : 8400001
-
Boerne, Texas, Spojené státy, 78006
- South Texas Medical Research Institute - TTS Research- Site Number : 8400010
-
Dallas, Texas, Spojené státy, 75246
- Baylor University Medical Center- Site Number : 8400002
-
El Paso, Texas, Spojené státy, 79903
- Western Sky Medical Research- Site Number : 8400023
-
McKinney, Texas, Spojené státy, 75069
- Metroplex Pulmonary and Sleep Center- Site Number : 8400022
-
-
-
-
-
Taipei, Tchaj-wan, 110
- Investigational Site Number : 1580003
-
-
-
-
-
Bursa, Turecko (Türkiye), 16059
- Investigational Site Number : 7920006
-
Istanbul, Turecko (Türkiye), 34098
- Investigational Site Number : 7920002
-
Istanbul, Turecko (Türkiye), 34854
- Investigational Site Number : 7920003
-
Kayseri, Turecko (Türkiye), 38039
- Investigational Site Number : 7920007
-
Kirikkale, Turecko (Türkiye), 71100
- Investigational Site Number : 7920008
-
Mersin, Turecko (Türkiye), 33070
- Investigational Site Number : 7920001
-
İzmit, Turecko (Türkiye), 41001
- Investigational Site Number : 7920005
-
-
-
-
-
Beijing, Čína, 100144
- Investigational Site Number : 1560011
-
Changchun, Čína, 130021
- Investigational Site Number : 1560010
-
Changsha, Čína, 410015
- Investigational Site Number : 1560017
-
Chengde, Čína, 067020
- Investigational Site Number : 1560021
-
Guangzhou, Čína, 510150
- Investigational Site Number : 1560009
-
Guangzhou, Čína, 510000
- Investigational Site Number : 1560053
-
Guangzhou, Čína, 510163
- Investigational Site Number : 1560001
-
Guiyang, Čína, 550002
- Investigational Site Number : 1560037
-
Hefei, Čína, 230032
- Investigational Site Number : 1560006
-
Hohhot, Čína, 010050
- Investigational Site Number : 1560014
-
Lanzhou, Čína, 730000
- Investigational Site Number : 1560030
-
Nanchang, Čína, 330006
- Investigational Site Number : 1560007
-
Pingxiang, Čína, 337055
- Investigational Site Number : 1560002
-
Shanghai, Čína, 200433
- Investigational Site Number : 1560013
-
Shenyang, Čína, 110004
- Investigational Site Number : 1560015
-
Taiyuan, Čína, 030001
- Investigational Site Number : 1560057
-
Tianjin, Čína, 300211
- Investigational Site Number : 1560055
-
Wenzhou, Čína, 325027
- Investigational Site Number : 1560005
-
Wuhan, Čína, 430030
- Investigational Site Number : 1560003
-
Wuhan, Čína, 430030
- Investigational Site Number : 1560022
-
Xuzhou, Čína, 221006
- Investigational Site Number : 1560004
-
Yangzhou, Čína, 225000
- Investigational Site Number : 1560016
-
Zhanjiang, Čína, 524004
- Investigational Site Number : 1560012
-
-
-
-
-
Madrid, Španělsko, 28007
- Investigational Site Number : 7240008
-
Madrid, Španělsko, 28010
- Investigational Site Number : 7240011
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Španělsko, 08017
- Investigational Site Number : 7240009
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol
-
Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:
- For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
- For Study ACT18301: LABA with or without LTRA
-
Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures
-
Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:
For female participants:
- incapable of becoming pregnant, or
- not pregnant or breast feeding
- no eggs donation or cryopreserving eggs
For male participants:
-- No sperm donation or cryopreserving sperm
- Capable of giving signed informed consent
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
- Participant who was diagnosed with a new pulmonary disease which may impair lung function
- Current smoker or active vaping of any products and/or marijuana smoking
- Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
- History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
- Participants who are receiving prohibited concomitant medications
- Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Lunsekimig
Participants will receive subcutaneous injection of lunsekimig according to established dosing interval |
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Časové okno: From study baseline to week 148
|
Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year. |
From study baseline to week 148
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Annualized rate of asthma exacerbation events
Časové okno: From study baseline to weeks 48, 96 and 144
|
From study baseline to weeks 48, 96 and 144
|
|
|
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Časové okno: From parent study baseline to weeks 48, 96 and 144
|
From parent study baseline to weeks 48, 96 and 144
|
|
|
Serum lunsekimig concentrations
Časové okno: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Časové okno: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Časové okno: From parent study baseline to weeks 48, 96 and 144
|
The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control. |
From parent study baseline to weeks 48, 96 and 144
|
|
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Časové okno: From parent study baseline to weeks 48, 96 and 144
|
Defined as ACQ-5 responder analysis |
From parent study baseline to weeks 48, 96 and 144
|
|
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Časové okno: From parent study baseline to weeks 48, 96 and 144
|
The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life. |
From parent study baseline to weeks 48, 96 and 144
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- LTS17231
- 2025-522896-27 (Identifikátor registru: CTIS)
- U1111-1303-3645 (Identifikátor registru: ICTRP)
- 2025 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .